Rise in innovative therapies & medications upswings the Global atopic dermatitis drugs market at 4.77% CAGR by 2027
“According to the new market research report published by Inkwood Research, the global atopic dermatitis drugs market is propelling at a CAGR of 4.77% during the forecasting years.”
“Browse 46 market Data Tables and 36 Figures spread over 150 Pages, along with an in-depth TOC on global pain management drugs market forecast 2019-2027”
A chronic, pruritic inflammatory skin disease, atopic dermatitis is a type of eczema that usually occurs in early infancy due to the elevated levels of immunoglobulin E in the bloodstream, but are also known to harm a substantial number of adults also. Some of the commonly known risk factors are inhalants, food allergens or in some cases, even the genetic makeup or heritability can increase the chances of occurrence. Environmental factors like low humidity, seasonal allergies, exposure to harsh soaps and detergents and cold weather can also trigger or worsen the condition of AD.
Righer prevalence of food allergies is uprising the demand for Atopic dermatitis drugs
Infants who are diagnosed with atopic dermatitis have a higher probability of getting affected by food allergies. Most of the common allergens that instigate the condition after the consumption of chicken eggs, fish, nuts, soy, cow’s milk, peanuts and wheat. Many studies show that at least 5-10 % of children throughout the world, who are diagnosed with atopic dermatitis, one-third of them are afflicted with food allergy. 15% of the infants aged three to 18 months with mild atopic dermatitis also suffer through certain food allergies. Thus, the higher the number of cases of food allergies in infants, higher will be the subsequent AD cases which are expected to augment the market growth indirectly.
To learn more about this report, request a free sample copy
Topical Route of Administration: key area of development for the market
Topical drugs are applied directly on to the skin or mucous membrane for local action. They are also known to reduce long term dermatitis conditions very efficiently, which is one of the many benefits that have been discovered till now. That’s there has been a gradual paradigm shift of patients opting for topical medications and specialty clinics, instead of the hospitals, for the preference of self-management of atopic dermatitis conditions in a quick manner. Henceforth, the market for topical atopic dermatitis drugs will have substantial growth opportunities in the future. To treat mild to moderate eczema or control rashes, patients prefer to employ topical steroid medications or topical calcineurin inhibitors.
North America is the significant contributor in the global atopic dermatitis drugs market
There have been many studies that have suggested that the frequency of eczema is getting higher in adults as most children afflicted with atopic dermatitis continue to be affected even in adulthood. And furthermore, the United States hosts at least 3% of the world’s adult population with moderate to severe eczema cases. This large number of the customer base, however, is creating large numbers of unmet needs for the treatment of individuals with eczema in North America. There are new varieties of therapies and medications in the atopic dermatitis drugs market in the region that are going to increase the turnout of patients in the upcoming years, that will propel the atopic dermatitis drugs market in North America to grow at 4.17% during 2019-2027.
Notable players in the global atopic dermatitis drugs market
Sanofi SA, Galderma SA, Bayer AG, Encore Dermatology, Leo Pharma, Novartis AG, Stiefel Laboratories Inc., Biofrontera AG, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Allergan PLC, Meda Pharmaceuticals (Mylan N.V.), Astellas Pharma Inc., Valent Pharmaceutical Inc., Pfizer, Aqua Pharmaceuticals (An Almirall Company).
About Inkwood Research
Inkwood Research specializes in syndicated & customized research reports and consulting services. Market intelligence studies with relevant fact-based research are customized across industry verticals such as technology, automotive, chemicals, materials, healthcare, and energy; with an objective comprehension that acknowledges the business environments. Our geographical analysis comprises of North & South America, CEE, CIS, Middle East, Europe, Asia, and Africa.